Product manufactured by Sti Pharma, Llc

Application Nr Approved Date Route Status External Links
NDA016320 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Myambutol Is Indicated For The Treatment Of Pulmonary Tuberculosis. It Should Not Be Used As The Sole Antituberculous Drug, But Should Be Used In Conjunction With At Least One Other Antituberculous Drug. Selection Of The Companion Drug Should Be Based On Clinical Experience, Considerations Of Comparative Safety, And Appropriate In-Vitro Susceptibility Studies. In Patients Who Have Not Received Previous Antituberculous Therapy, Ie, Initial Treatment, The Most Frequently Used Regimens Have Been The Following: Myambutol Plus Isoniazid Myambutol Plus Isoniazid Plus Streptomycin. In Patients Who Have Received Previous Antituberculous Therapy, Mycobacterial Resistance To Other Drugs Used In Initial Therapy Is Frequent. Consequently, In Such Retreatment Patients, Myambutol Should Be Combined With At Least One Of The Second Line Drugs Not Previously Administered To The Patient And To Which Bacterial Susceptibility Has Been Indicated By Appropriate In-Vitro Studies. Antituberculous Drugs Used With Myambutol Have Included Cycloserine, Ethionamide, Pyrazinamide, Viomycin And Other Drugs. Isoniazid, Aminosalicylic Acid, And Streptomycin Have Also Been Used In Multiple Drug Regimens. Alternating Drug Regimens Have Also Been Utilized.

All Formulated Excipients (0 Total)


Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Ethambutol Hydrochloride ETHAMBUTOL HYDROCHLORIDE ZINC19364219